Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01658800 · ClinicalTrials.gov registry record · Phase 1
Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49
A Phase 1 study, sponsored by VaxInnate Corporation.
- Completed
- Registry status
- Phase 1
- Development phase
- 275
- Enrollment target
NCT01658800 is a Phase 1 study that has completed, run by VaxInnate Corporation. The registered enrollment target is 275 participants.
The verdict
NCT01658800, a Phase 1 study, has completed, sponsored by VaxInnate Corporation.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 275 participants
- Enrollment target
Study Summary
The purpose of this study is to test an investigational vaccine known as "VAX161C." An "investigational" vaccine is one that is not licensed for commercial use in the by the United States (US) by the US Food and Drug Administration (FDA). VAX161C is a vaccine for the influenza A virus subtype H5N1 avian influenza virus (bird flu). In this study, the subject will receive the VAX161C vaccine at one of six doses to see which dose is the best. VaxInnate wants to find out how safe these doses of vaccines are and how well they are tolerated by people who receive them. To measure how effective each type of the vaccine is, VaxInnate will test the ability of the body to develop an immune response, which means how the body recognizes and defends itself against the influenza virus.
Interventions
- BIOLOGICAL VAX161C vaccine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 275 participants |
| Start Date | 2012-09 |
| Est. Completion | 2013-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01658800
The ClinicalTrials.gov registry entry for NCT01658800 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 275 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VaxInnate Corporation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VAX161C vaccine is the first listed.
NCT01658800 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01658800 about?
NCT01658800 is a clinical study titled "Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49". The purpose of this study is to test an investigational vaccine known as "VAX161C." An "investigational" vaccine is one that is not licensed for commercial use in the by the United States (US) by the US Food and Drug Administration (FDA). VAX161C is a vaccine for the influenza A virus subtype H5N1 a...
What is the current status of trial NCT01658800?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 275 participants. The study started on 2012-09. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01658800?
The interventions under investigation include: VAX161C vaccine (BIOLOGICAL).
Who is sponsoring clinical trial NCT01658800?
This trial is sponsored by VaxInnate Corporation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.